Investment Thesis
BioXcel Therapeutics faces critical financial distress with negative stockholders' equity of -$95.5M, net losses of -$69.9M, and operating cash burn of -$57.6M annually. Revenue has collapsed 71.7% to just $642K, while the company carries $109.6M in long-term debt against only $28.4M cash, leaving less than 6 months of operational runway. The company is technically insolvent with no visible path to profitability.
Strengths
- Maintains $28.4M in cash (provides temporary liquidity buffer)
- Total assets of $44.9M provide some liquidation value
- Recent insider activity (8 Form 4 filings) indicates management engagement
Risks
- Negative stockholders' equity of -$95.5M indicates technical insolvency
- Revenue collapsed 71.7% YoY to minimal $642K generation
- Operating cash burn of -$57.6M annually with <6 months runway to depletion
- Long-term debt of $109.6M dwarfs available assets; likely covenant breaches imminent
- Current ratio of 0.83x signals acute liquidity crisis and inability to meet short-term obligations
- Extreme profitability metrics: -10,887% net margin and -7,860% operating margin
Key Metrics to Watch
- Quarterly cash burn trajectory and months of runway remaining
- Revenue stabilization and pipeline execution
- Debt covenant compliance status and refinancing negotiations
- Restructuring, asset sale, or merger announcements
Financial Metrics
Revenue
642.0K
Net Income
-69.9M
EPS (Diluted)
$-5.73
Free Cash Flow
-57.6M
Total Assets
44.9M
Cash
28.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-7,860.0%
Net Margin
-10,887.4%
ROE
N/A
ROA
-155.6%
FCF Margin
-8,974.3%
Balance Sheet & Liquidity
Current Ratio
0.83x
Quick Ratio
0.82x
Debt/Equity
N/A
Debt/Assets
312.5%
Interest Coverage
-3.29x
Long-term Debt
109.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T08:00:35.916570 |
Data as of: 2025-12-31 |
Powered by Claude AI